Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study

被引:50
作者
Figueiredo, Jane C.
Ennis, Marguerite
Knight, Julia A.
McLaughlin, John R.
Hood, Nicky
O'Malley, Frances
Andrulis, Irene L.
Goodwin, Pamela J.
机构
[1] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
[2] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5T 3L9, Canada
[3] Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON, Canada
[4] Canc Care Ontario, Div Prevent Oncol, Toronto, ON, Canada
[5] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada
[6] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON, Canada
关键词
breast cancer; family history; young age; tumor pathology; treatment; survival; population-based; prospective;
D O I
10.1007/s10549-006-9433-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The objective of this study was to examine the association of: (i) diagnosis at age <= 35, (ii) first-degree family history of breast or ovarian cancer (BOC) and (iii) a research based definition of genetic risk, with tumor characteristics, treatment and survival in breast cancer (BC). Patients and methods Consenting female participants in the population-based Ontario Familial Breast Cancer Registry diagnosed with primary invasive BC between 1996 and 1998 were followed prospectively until 2005. Results Among 967 women, 105 were <= 35 years old at diagnosis and 686 were classified as genetic risk cases, including 349 with a first-degree family history. Individuals diagnosed at age <= 35 were more likely to self-detect tumors, to present with inflammatory BC, to have invasive ductal carcinoma of no special type, high T stage, and tumors with lymphovascular invasion (LVI), high grade and negative estrogen receptors. Younger women were more likely to receive chemotherapy and less likely to receive hormonal therapy. Diagnosis <= 35 years old was associated with significantly reduced distant recurrence free survival, an effect that did not persist after adjustment for tumor and treatment related variables. Poor outcomes were restricted to younger women with hormone responsive BC. Family history was associated with increased rates of mammographic detection of BC, lower tumor stage and less frequent inflammatory BC, but had no association with BC outcomes. Conclusion Women diagnosed with BC at age <= 35 have more aggressive tumors; these adverse tumor characteristics, rather than age, lead to poor outcomes. Family history was not associated with survival.
引用
收藏
页码:69 / 80
页数:12
相关论文
共 54 条
[1]   THE RELATION BETWEEN SURVIVAL AND AGE AT DIAGNOSIS IN BREAST-CANCER [J].
ADAMI, HO ;
MALKER, B ;
HOLMBERG, L ;
PERSSON, I ;
STONE, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (09) :559-563
[2]   Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? [J].
Aebi, S ;
Gelber, S ;
Castiglione-Gertsch, M ;
Gelber, RD ;
Collins, J ;
Thürlimann, B ;
Rudenstam, CM ;
Lindtner, J ;
Crivellari, D ;
Cortes-Funes, H ;
Simoncini, E ;
Werner, ID ;
Coates, AS ;
Goldhirsch, A .
LANCET, 2000, 355 (9218) :1869-1874
[3]  
Andrulis IL, 1997, CAN FAM PHYSICIAN, V43, P949
[4]   Effecting behavior change - Awareness of family history [J].
Audrain-McGovern, J ;
Hughes, C ;
Patterson, F .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2003, 24 (02) :183-189
[5]   AGE AS A PROGNOSTIC FACTOR IN BREAST-CANCER - RELATIONSHIP TO PATHOLOGICAL AND BIOLOGIC FEATURES [J].
BONNIER, P ;
ROMAIN, S ;
CHARPIN, C ;
LEJEUNE, C ;
TUBIANA, N ;
MARTIN, PM ;
PIANA, L .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (02) :138-144
[6]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003
[7]  
Chung M, 1996, CANCER, V77, P97, DOI 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO
[8]  
2-3
[9]   Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93 [J].
Colleoni, M ;
Gelber, S ;
Goldhirsch, A ;
Aebi, S ;
Castiglione-Gertsch, M ;
Price, KN ;
Coates, AS ;
Gelber, RD .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1332-1341
[10]   Very young women (&lt;35 years) with operable breast cancer:: features of disease at presentation [J].
Colleoni, M ;
Rotmensz, N ;
Robertson, C ;
Orlando, L ;
Viale, G ;
Renne, G ;
Luini, A ;
Veronesi, P ;
Intra, M ;
Orecchia, R ;
Catalano, G ;
Galimberti, V ;
Nolé, F ;
Martinelli, G ;
Goldhirsch, A .
ANNALS OF ONCOLOGY, 2002, 13 (02) :273-279